Pregnancy-associated malaria and the prospects for syndrome-specific antimalaria vaccines.
Aided by the Plasmodium falciparum genome project, recent discoveries regarding the molecular basis of malaria pathogenesis have led to a better understanding of the interactions between host and parasite. Although vaccines that prevent infection by malaria parasites remain only hopes for the future, there are now more immediate prospects for vaccines that protect against specific disease syndromes. Here, we discuss the latest advances in the development of a vaccine that specifically targets pregnancy-associated malaria (PAM).
Smith
Joseph D
JD
Seattle Biomedical Research Institute, 307 Westlake Ave. N., Ste. 500, Seattle, WA 98109-5219, USA. joe.smith@sbri.org
Deitsch
Kirk W
KW
D000818:Animals; D002809:Chondroitin Sulfates / Q000378:metabolism; D004912:Erythrocytes / Q000378:metabolism / Q000469:parasitology; D005260:Female; D006790:Host-Parasite Interactions; D006801:Humans; D017780:Malaria Vaccines; D016778:Malaria, Falciparum / Q000517:prevention & control*; D010920:Placenta / Q000469:parasitology; D010963:Plasmodium falciparum / Q000276:immunology*; D011247:Pregnancy / Q000276:immunology*; D015800:Protozoan Proteins / Q000235:genetics / Q000378:metabolism
D017780:Malaria Vaccines; D015800:Protozoan Proteins; C085731:erythrocyte membrane protein 1, Plasmodium falciparum; D002809:Chondroitin Sulfates